IPOs

Oncology biotech Aprea Therapeutics prices upsized IPO at $15 midpoint

Aprea Therapeutics, a Phase 3 biotech developing targeted therapies for cancer, raised $85 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. The company upsized its offering by 0.67 million shares ($10 million).

Aprea Therapeutics plans to list on the Nasdaq under the symbol APRE. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as lead managers on the deal.

Oncology biotech Aprea Therapeutics prices upsized IPO at $15 midpoint

Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

APRE